Pharmacotherapy for Acute Coronary Syndrome: A Benefit Risk Assessment: Nationwide Population-Based Cohort Study in Taiwan
Preise von
103,20
Hervorgehoben
|
103,20 € |
Zum Shop
|
|
103,20 € |
Zum Shop
|
| ALLE WEBSHOPS VERGLEICHEN (2) | ||
Beschreibung
Pharmacotherapy for Acute Coronary Syndrome: A Benefit Risk Assessment: Nationwide Population-Based Cohort Study in Taiwan
Beschreibung
(0)
Pharmacotherapy for Acute Coronary Syndrome: A Benefit Risk Assessment: Nationwide Population-Based Cohort Study in Taiwan
Produktspezifikationen
Verwandte Ergebnisse
Hervorgehobene Wahl
103,20 €
